Echo: Orphan Drug Manufacturers Marketing Off-Label
Nolan Auerbach & White addressed orphan off label drug marketing in our blog on November 10, 2015. Orphan Drugs are used in the diagnosis, prevention and/or treatment…
Read More »Pharma 101 – Pharmaceutical Fraud
Pharmaceutical Fraud News & Insight form the Qui Tam and False Claims Act Perspective
Contact FormCategory Archives: off label
Are Orphan Drug Manufacturers Ramping Up Off-Label Marketing Efforts?
Fraud goes where money flows. This statement is particularly true in the growing prescription drug market, which has been fraught with illegal marketing schemes for…
Read More »False Claims Act Will Always Reach Off-Label Pharmaceutical Promotions When Promotions Include False or Misleading Information
Nearly three years ago, the Second Circuit Court of Appeals vacated the criminal conviction of a pharmaceutical sales representative, who was convicted of conspiring to…
Read More »How to Stop the Criminal Enterprise of Off-label Pediatric Promotions
A pharmaceutical drug achieves an approved indication for pediatric patients only after undergoing clinical trials in children, and the FDA’s strictest review of data to…
Read More »SDNY Transfers Off-Label Promotion FCA Case That Potentially Implicated Caronia
In 2012, in United States v. Caronia, the Second Circuit overturned a criminal conviction of a pharmaceutical sales representative, holding that off-label promotions may be constitutionally-protected…
Read More »Wyeth Pharmaceuticals Pays $409.9 Million for Allegedly Illegally Marketing Transplant Drug
Wyeth Pharmaceuticals Inc., a pharmaceutical company acquired by Pfizer, Inc. in 2009, has agreed to pay $490.9 million to resolve its criminal and civil liability…
Read More »Fraud Hunting Season Remains Open for Off-Label Marketing Schemes
For weeks, the United States Department of Justice has signaled that it will continue to vigorously pursue illegal off-label marketing schemes deployed by dishonest pharmaceutical…
Read More »Whistleblowers Assist Government in Recovering $762 Million in Ill-Gotten Gains from Biotechnology Giant Amgen
Amgen Inc. agreed to pay $612 million to resolve civil healthcare fraud allegations that the company unlawfully promoted its anemia drug Aranesp and other medications,…
Read More »Boehringer Ingelheim Pharmaceuticals Pays $95 Million for Illegally Promoting Drugs for Unapproved Uses and Dosages
Another pharmaceutical giant recently agreed to return millions of dollars to federal and state governments for causing false claims arising out of off-label marketing its…
Read More »Were Johnson & Johnson’s Risperdal Sales Inflated by Illegal Promotions?
In 1993, the FDA approved Johnson & Johnson’s drug Risperdal for the limited use of treating a few psychotic disorders, including schizophrenia. However, even with…
Read More »